Adjuvant Therapy of Operable Primary Osteosarcoma-Cancer and Leukemia Group B Experience
The major therapeutic approach to primary osteogenic sarcoma has, for many years, been radical surgery. Despite differences in pretherapeutic work-up, surgical techniques, and demography, the overall survival rates in the review of Friedman and Carter was 19.7% (253 of 1286 patients) . The range was fairly small, 16%–23% in the series published. Radiologic evidence of pulmonary metastases occurs at a median of 8.5 months after potentially curative amputation . The patient usually dies within 6 months from the onset of detectable pulmonary metastases .
KeywordsToxicity Leukemia Creatinine Pneumonia Oncol
Unable to display preview. Download preview PDF.
- 2.Cortes, E. P., Holland, J. F., Wang, J. J. et al.: Chemotherapy of advanced osteosarcoma. Colston paper No. 24. In: Bone-certain aspects of neoplasia price, CHG, Rose, F. G. M. (eds.), pp. 265–280. London: Butterworth 1972.Google Scholar
- 4.Cortes, E. P., Holland, J. F., Wang, J. J. et al.: Adriamycin (NSC-123127) in 87 patients with osteosarcoma. Cancer Chemother. Rep. (Part 3) 6, 305–313 (1975).Google Scholar
- 5.Cortes, E. P., Lutman, G., Wanka, J. et al.: Adriamycin (NSC-123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother. Rep. (Part 3), 6, 215–225 (1975).Google Scholar
- 10.Marcove, R. C., Mike, V., Hajek, J. V. et al.: Osteogenic sarcoma in childhood. NY State J. Med. 71, 855–859 (1971).Google Scholar
- 11.McKenna, R. J., Schwinn, C. P., Soong, K. Y. et al.: Sarcoma of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone): an analysis of 552 cases. J. Bone Joint Surg. 48, 1–26 (1966).Google Scholar
- 13.Sweetnam, R.: Amputation in osteosarcoma. J. Bone Joint Surg. 55 B, 189–192 (1973).Google Scholar